XML 50 R41.htm IDEA: XBRL DOCUMENT v3.23.3
Partnerships - Additional Information (Details)
¥ in Billions
 1 Months Ended 3 Months Ended 9 Months Ended 31 Months Ended
Dec. 31, 2022
USD ($)
May 31, 2017
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2023
USD ($)
Nov. 30, 2019
shares
Nov. 03, 2023
USD ($)
Sep. 30, 2023
JPY (¥)
Dec. 05, 2022
USD ($)
Dec. 05, 2022
JPY (¥)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Recognized revenue     $ 8,870,000 $ 26,873,000          
Deferred revenue current $ 14,700,000   15,832,000 15,832,000          
Deferred revenue long term 10,378,000   2,420,000 2,420,000          
Ono | Asset Purchase Agreement                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Upfront non-refundable and non-creditable payment receivable, upon exchange of option               $ 26,400,000 ¥ 3.5
One-time payment receivable, upon exercises the option     33,300,000 $ 33,300,000     ¥ 5.0    
Option period expiry condition       the option period will expire three months following the delivery of topline data from the EQUALISE clinical study in lupus nephritis and interim data from the EQUATOR Phase 3 clinical study in acute graft-versus-host disease.          
Upfront non-refundable and non-creditable payment invoiced               25,800,000 ¥ 3.5
Upfront payment received 26,400,000                
Foreign curreny realized gain $ 600,000                
Initial transaction price               102,600,000  
Upfront and non-creditable payment invoiced               25,800,000  
Estimated research and development funding               76,800,000  
Deferred revenue     18,200,000 $ 18,200,000       $ 25,800,000  
Recognized revenue     8,900,000 26,900,000          
Deferred revenue current     15,800,000 15,800,000          
Deferred revenue long term     2,400,000 2,400,000          
Proceeds from research and development fees       31,300,000          
Ono | Asset Purchase Agreement | Research and Development Services                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Recognized revenue     6,700,000 20,100,000          
Ono | Asset Purchase Agreement | Upfront Payment Amortization                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Recognized revenue     $ 2,200,000 $ 6,800,000          
Ono | Asset Purchase Agreement | Maximum | Subsequent Event                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Eligible to receive payment on achievement of certain development milestones           $ 101,400,000      
Biocon                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Common stock shares issued | shares         2,316,134        
Biocon | Collaboration and License Agreement                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Regulatory milestone payments   $ 30,000,000              
Sales milestone payments   $ 565,000,000